Discover the range of academic oncology titles at Springer Nature here.
Featured Review - ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
In this review, we summarize existing knowledge surrounding the mechanisms of action of ESR1 mutations and roles in resistance to aromatase inhibition. We then analyze the recent literature on how ESR1 mutations affect outcomes in estrogen receptor-targeting and combination therapies.
Aims and scope
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
Articles
-
-
18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
-
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
-
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
-
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
-
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
-
Choosing the right cell line for breast cancer research
-
Breast asymmetry and predisposition to breast cancer
-
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
-
Mouse models of breast cancer metastasis
Editor-in-Chief
Lewis Chodosh, University of Pennsylvania, USA
Trending in the Media
Click here to see the most popular articles published in Breast Cancer Research in the past three months.
Springer Nature Oncology Portfolio
BCR's 20th Anniversary
20 years ago Breast Cancer Research published its first articles with BMC. Well-respected in the field, the journal has continually placed in the first quartile of the ‘Oncology’ category of Journal Citation Reports. Over the past decade, Breast Cancer Research (BCR) has also become the highest ranked breast cancer focused title in the field.
Look back at the journal’s milestone achievements and article highlights.
From the blog
COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Follow
Annual Journal Metrics
-
Speed
75 days to first decision for reviewed manuscripts only
38 days to first decision for all manuscripts
153 days from submission to acceptance
20 days from acceptance to publicationCitation Impact
6.466 - 2-year Impact Factor
7.426 - 5-year Impact Factor
1.466 - Source Normalized Impact per Paper (SNIP)
2.378 - SCImago Journal Rank (SJR)Usage
1,603,696 Downloads
5802 Altmetric Mentions